A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

Trial Profile

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2013

At a glance

  • Drugs Cevimeline (Primary)
  • Indications Alzheimer's disease; Xerostomia
  • Focus Pharmacokinetics
  • Sponsors Roxane Laboratories
  • Most Recent Events

    • 04 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top